High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma

Journal of Ovarian Research

Research

Svenja Kolb¹  Eliane T. Taube²  Mihnea P. Dragomir²  Christine Sers²  David Horst²  Philip Bischoff²  Catarina Alisa Kunze²  Inga Hoffmann²  Wolfgang D. Schmitt²  Paul Jank³  Carsten Denkert³  Moritz Jesinghaus³  Christina Westhoff³  Moritz Gleitsmann³  Albrecht Stenzinger⁴  Jonas Leichsenring⁵  Stefan Gröschel⁶  Hagen Kulbe⁷  Ioana Elena Braicu⁷  Jalid Sehouli⁷ 

[1] Department of Gynecology, Vivantes Netzwerk Für Gesundheit GmbH Berlin, Vivantes Hospital Neukölln, Rudower Straße 48, 12351, Berlin, Germany;Institute of Pathology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität Zu Berlin, CCM, Charitéplatz 1, 10117, Berlin, Germany;Institute of Pathology, Philipps-University Marburg, University Hospital Marburg (UKGM), Marburg, Germany;Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany;Institute of Pathology, Zytologie Und Molekulare Diagnostik, REGIOMED, Klinikum Coburg, Coburg, Germany;Oncology Center Worms, Worms, Germany;Tumorbank Ovarian Cancer Network, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany;Department of Gynecology, European Competence Center for Ovarian Cancer, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany;

关键词: Ovarian cancer;    Biomarker;    Prognostic biomarker;    HGSOC;    EVI1;    PARP;   

DOI  :  10.1186/s13048-023-01239-6

 received in 2023-03-23, accepted in 2023-07-16,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundMechanisms of development and progression of high-grade serous ovarian cancer (HGSOC) are poorly understood. EVI1 and PARP1, part of TGF-ß pathway, are upregulated in cancers with DNA repair deficiencies with DNA repair deficiencies and may influce disease progression and survival. Therefore we questioned the prognostic significance of protein expression of EVI1 alone and in combination with PARP1 and analyzed them in a cohort of patients with HGSOC.MethodsFor 562 HGSOC patients, we evaluated EVI1 and PARP1 expression by immunohistochemical staining on tissue microarrays with QuPath digital semi-automatic positive cell detection.ResultsHigh EVI1 expressing (> 30% positive tumor cells) HGSOC were associated with improved progression-free survival (PFS) (HR = 0.66, 95% CI: 0.504–0.852, p = 0.002) and overall survival (OS) (HR = 0.45, 95% CI: 0.352–0.563, p < 0.001), including multivariate analysis. Most interestingly, mutual high expression of both proteins identifies a group with particularly good prognosis. Our findings were proven technically and clinically using bioinformatical data sets for single-cell sequencing, copy number variation and gene as well as protein expression.ConclusionsEVI1 and PARP1 are robust prognostic biomarkers for favorable prognosis in HGSOC and imply further research with respect to their reciprocity.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

Fig. 4

Fig. 5

Fig. 4

Fig. 2

Fig. 1

13690_2023_1147_Article_IEq10.gif

Fig. 3

Fig. 2

Fig. 1